Wendy St. Peter, PharmD, explains how the new cardio-kidney-metabolic (CKM) syndrome guideline supports pharmacist-led medication management, staging tools, and de-prescribing.
In an interview with Pharmacy Times, Wendy L. St. Peter, PharmD, FCCP, FASN, FNKF, professor emerita at the University of Minnesota College of Pharmacy and a writing committee member for the new cardio-kidney-metabolic (CKM) syndrome guideline, discussed how the guideline supports pharmacist-led comprehensive medication management (CMM) for patients with CKM syndrome. St. Peter highlighted Section 5 and Table 12 of the guideline, which identify CMM as a key component of coordinated, interdisciplinary care—marking the first time a major guideline has formally recognized CMM as a standard of practice.
She noted that although models for pharmacist-led clinical services vary across the country due to fragmented health systems and state-specific scope-of-practice laws, pharmacists are uniquely positioned to lead this work. St. Peter also detailed 2 essential tools for managing therapy in patients with declining kidney function alongside cardiovascular and metabolic risk: the Kidney Disease: Improving Global Outcomes (KDIGO) heat map for CKD staging and the American Heart Association PREVENT calculator, which incorporates estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR). She explained how eGFR thresholds affect the initiation of therapies like sodium-glucose cotransporter 2 (SGLT2) inhibitors and finerenone (Kerendia; Bayer) and discussed how pharmacists can approach deprescribing—such as discontinuing sulfonylureas when initiating a glucagon-like peptide-1 (GLP-1) receptor agonist—depending on their collaborative practice agreement status.
Pharmacy Times: How does this guideline support pharmacist-led comprehensive medication management for patients with CKM syndrome, and what does that look like as a clinical service?
Wendy L. St. Peter, PharmD, FCCP, FASN, FNKF: Well, let's talk about how it supports pharmacist-led CMM. First, I want to tell pharmacists to go to Section 5 in the new CKM guideline, which specifically addresses interdisciplinary care and the need for care coordination. Within Table 12 in that section, it highlights that CMM is a key component of coordinated health services. As far as I'm aware, this is the first time a major health guideline has included CMM as a standard of practice to ensure that patients' medications are individually assessed—to make sure each one is indicated and effective for their medical conditions, safe given their comorbidities and other medications, and can be taken as intended. This is really a big deal, and the guideline recognizes that a pharmacist is an essential part of the interdisciplinary care team. I think pharmacists can use this national recognition to advocate for holistic, comprehensive medication management services for persons with CKM syndrome with their institution's leaders and C-suite administrators.
As far as what this looks like as a clinical service, the guideline didn't explicitly say that a pharmacist is the only professional who can provide CMM, but it's widely recognized that pharmacists have the best training to provide it. This guideline points to several randomized controlled studies that support utilization of pharmacists to facilitate initiation and follow-up of these evidence-based therapies for CKM conditions. However, I think it's widely recognized by most pharmacists that models for pharmacist clinical services vary across the United States, and in these studies it also varied—which isn't surprising given the diverse and fragmented health care systems we have in the US today, as well as state-specific pharmacy practice acts and rules that can limit pharmacists' scope of practice. As pharmacists, we really need to continue to advocate for changes in state practice acts, as well as legislation at the federal level, to recognize pharmacists as health care providers so we can implement a true, standardized comprehensive medication management practice across the country.
Pharmacy Times: What should pharmacists be paying closest attention to when managing therapy for patients whose kidney function is declining alongside cardiovascular and metabolic risk?
St. Peter: First, we need to classify patients into a CKD stage using the KDIGO heat map—KDIGO being the Kidney Disease: Improving Global Outcomes international guideline body—to determine a person's risk for CKD progression and kidney failure. Second, we need to use the new American Heart Association PREVENT calculator, which incorporates all the standard key metabolic and cardiovascular risk factors but in addition includes eGFR and UACR. All these factors go into the risk equation, and it will determine the patient's risk for cardiovascular disease. We can then use that information to determine the CKM stage, and once we do that, the guideline helps pharmacists decide which evidence-based therapies should be considered.
Knowing the patient's eGFR—their kidney function—is important for determining whether specific therapies can be initiated. For example, we know that SGLT2 inhibitors aren't indicated when someone's eGFR is less than 20, and the nonsteroidal mineralocorticoid receptor antagonist finerenone is not recommended for initiation when the eGFR is less than 20, due to increased risk of hyperkalemia. And of course, as pharmacists, we all know it's important to use kidney function assessment—I use eGFR adjusted for a person's body surface area—to determine dosing adjustments for many medications.
Pharmacy Times: Does this guideline give pharmacists more standing to lead deprescribing conversations or simplify regimens, and how should that be approached?
St. Peter: That's a really good question. I think of deprescribing as a component of a standardized, comprehensive medication management practice, but of course, state-specific pharmacist scope of practice will dictate how pharmacists can approach deprescribing. If a pharmacist practices under a broad collaborative practice agreement (CPA), then deprescribing can be covered under that agreement. If the pharmacist practices under a more limited CPA, or no CPA, then they'll typically need to address deprescribing directly with the patient's physicians or advanced practice providers to get buy-in.
This is really important, because as we add on some of these guideline-directed therapies, like a GLP-1 receptor agonist, for instance, we should be thinking about taking off other therapies, like sulfonylureas, which don't impact a patient's progression to kidney disease or cardiovascular disease, but can increase the risk of hypoglycemia. It's really important for us to do this, and pharmacists will have to use different mechanisms to accomplish it.
